Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.58 |
| ▸ | PIK3C2G | O75747 | 2/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 9/20 | 0.55 |
| ▸ | TTK | P33981 | 5/20 | 0.55 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.52 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.52 |
| ▸ | STK4 | Q13043 | 1/20 | 0.52 |
| ▸ | BMPR2 | Q13873 | 5/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203361 | 0.90 | PLK1 (0.55) | PIK3CDPIK3C2GPIK3CGAURKADCLK1 | |
| SCHEMBL1202757 | 0.89 | STK4 (0.65) | PIK3CDPIK3C2GPIK3CGAURKADCLK1 | |
| SCHEMBL4297855 | 0.88 | PLK1 (0.59) | PLK1TTKPLK3PLK4GAK | |
| SCHEMBL12880190 | 0.87 | PIK3CD (0.54) | PIK3CDPIK3C2GPIK3CGAURKADCLK1 | |
| SCHEMBL1202938 | 0.87 | PLK1 (0.56) | PLK1TTKPLK3PLK2PLK4 | |
| SCHEMBL1203825 | 0.87 | PLK1 (0.59) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL15499826 | 0.86 | PLK1 (0.50) | PIK3CDPIK3C2GPIK3CGAURKADCLK1 | |
| SCHEMBL14320149 | 0.86 | PLK1 (0.60) | PLK1TTKPLK3PLK4GAK | |
| SCHEMBL1203566 | 0.86 | PLK1 (0.49) | PIK3CDPIK3C2GPIK3CGAURKADCLK1 | |
| SCHEMBL1203605 | 0.85 | PLK1 (0.63) | PLK1TTKPLK3PLK2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PIK3CD 678/4885PIK3C2G 2588/4885PIK3CG 1071/4885 |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PIK3CD 677/4885PIK3C2G 2681/4885PIK3CG 1127/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PIK3CD 190/4885PIK3C2G 1314/4885PIK3CG 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.